UOC
PDLI

UBS O'Connor’s PDL BioPharma, Inc. PDLI Stock Holding History

UBS O'Connor’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-145,480
Closed -$1.21M – 616
2014
Q1 		$1.21M Buy
+145,480
New +$1.25M 0.02% 311

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS O'Connor's PDLI Position: Q2 2014 in Review

UBS O'Connor sold out of PDL BioPharma, Inc. (PDLI) in Q2 2014, closing a stake of 145,480 shares — an estimated $1.21M sold.

UBS O'Connor first reported a position in PDLI in Q1 2014 and held it in 1 quarter. The position peaked at $1.21M in Q1 2014. 222 funds tracked by Wall St. Rank hold PDLI as of Q2 2014.

  • UBS O'Connor reported no remaining PDL BioPharma, Inc. position as of Q2 2014 after selling out during the quarter.
  • UBS O'Connor sold 145,480 PDL BioPharma, Inc. shares in Q2 2014, an estimated $1.21M.
  • UBS O'Connor first reported a position in PDL BioPharma, Inc. in Q1 2014 and held it in 1 quarter.
  • UBS O'Connor's PDL BioPharma, Inc. position peaked at $1.21M in Q1 2014.
  • 222 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2014.

Based on UBS O'Connor's 13F filing for Q2 2014, filed 15 Aug 2014.